XORTX Therapeutics (XRTX)
(Delayed Data from NSDQ)
$1.64 USD
-0.11 (-6.29%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $1.64 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for XORTX Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 6 | 10 | 3 | 1 | 0 |
Income After Depreciation & Amortization | -6 | -10 | -3 | -1 | 0 |
Non-Operating Income | 4 | 3 | 2 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -2 | -7 | -1 | -1 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -2 | -7 | -1 | -1 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -2 | -7 | -1 | -1 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -10 | -3 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -6 | -10 | -3 | -1 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.98 | 1.48 | 1.09 | 8.69 | NA |
Diluted EPS Before Non-Recurring Items | -2.95 | -4.95 | -2.52 | -0.09 | NA |
Diluted Net EPS (GAAP) | -1.09 | -4.92 | -1.22 | -1.28 | NA |
Fiscal Year end for XORTX Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 1.49 | 1.08 | 0.98 | 1.40 | 1.76 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.49 | -1.08 | -0.98 | -1.40 | -1.76 |
Non-Operating Income | 1.66 | -1.93 | 3.68 | 0.06 | 0.07 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 0.17 | -3.02 | 2.70 | -1.33 | -1.69 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.17 | -3.02 | 2.70 | -1.33 | -1.69 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.17 | -3.02 | 2.70 | -1.33 | -1.69 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 2.90 | 2.43 | 1.96 | 2.00 | 2.00 |
Diluted EPS Before Non-Recurring Items | 0.06 | -1.24 | -0.48 | -0.67 | -0.81 |
Diluted Net EPS (GAAP) | 0.06 | -1.24 | 1.38 | -0.67 | -0.81 |